Secukinumab Provides Sustained Improvements in the Signs and Symptoms in Psoriatic Arthritis: Final 5 Year Efficacy and Safety Results from a Phase 3 Trial

Conference contribution


Publication Details

Author(s): Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, Geusens P, Pascale P, Delicha EM, Pricop L, Mpofu S
Publication year: 2018
Volume: 70
ISSN: 2326-5191
eISSN: 2326-5205


External institutions with authors

Barts Health NHS Trust
Hasselt University / Universiteit Hasselt
Hospital of Southern Norway
Monash University
Novartis AG
Swedish Medical Center
University of California, San Diego


How to cite

APA:
Mease, P.J., Kavanaugh, A., Reimold, A., Tahir, H., Rech, J., Hall, S.,... Mpofu, S. (2018). Secukinumab Provides Sustained Improvements in the Signs and Symptoms in Psoriatic Arthritis: Final 5 Year Efficacy and Safety Results from a Phase 3 Trial.

MLA:
Mease, Philip J., et al. "Secukinumab Provides Sustained Improvements in the Signs and Symptoms in Psoriatic Arthritis: Final 5 Year Efficacy and Safety Results from a Phase 3 Trial." 2018.

BibTeX: 

Last updated on 2019-18-07 at 07:26